Literature DB >> 17251405

Lymphogranuloma venereum in Australia: anorectal Chlamydia trachomatis serovar L2b in men who have sex with men.

D Stark1, S van Hal, R Hillman, J Harkness, D Marriott.   

Abstract

Lymphogranuloma venereum (LGV) is a sexually transmitted infection that is causing an ongoing epidemic in men who have sex with men (MSM) in Europe, the United Kingdom, and North America. Twenty-nine rectal swabs positive for Chlamydia trachomatis were analyzed by real-time PCR for the presence of LGV serovars. Genotyping revealed an identical L2b serovar from four specimens. All patients were MSM and human immunodeficiency virus infected. Three of the four presented with severe ulcerative proctitis. We report a cluster of rectal LGV serovar L2b infections in Sydney, Australia.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17251405      PMCID： PMC1829134          DOI： 10.1128/JCM.02389-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  20 in total

1.  Emergence of lymphogranuloma venereum in Canada.

Authors:  Rhonda Y Kropp; Thomas Wong
Journal:  CMAJ       Date:  2005-05-31       Impact factor: 8.262

2.  Locally acquired lymphogranuloma venereum in a bisexual man.

Authors:  Damon P Eisen
Journal:  Med J Aust       Date:  2005-08-15       Impact factor: 7.738

3.  Anorectal lymphogranuloma venereum in a Melbourne man.

Authors:  Anna N Morton; Christopher K Fairley; Angelo M Zaia; Marcus Y Chen
Journal:  Sex Health       Date:  2006-09       Impact factor: 2.706

4.  Characterization of Chlamydia trachomatis omp1 genotypes among sexually transmitted disease patients in Sweden.

Authors:  M Jurstrand; L Falk; H Fredlund; M Lindberg; P Olcén; S Andersson; K Persson; J Albert; A Bäckman
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

5.  Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar l2 proctitis in The Netherlands among men who have sex with men.

Authors:  Rutger F Nieuwenhuis; Jacobus M Ossewaarde; Hannelore M Götz; Jan Dees; H Bing Thio; Maarten G J Thomeer; Jan C den Hollander; Martino H A Neumann; Willem I van der Meijden
Journal:  Clin Infect Dis       Date:  2004-09-08       Impact factor: 9.079

6.  Chlamydia trachomatis omp1 genotypic diversity and concordance with sexual network data.

Authors:  Teresa Cabral; Ann M Jolly; John L Wylie
Journal:  J Infect Dis       Date:  2003-01-06       Impact factor: 5.226

7.  Variability of the Chlamydia trachomatis omp1 gene detected in samples from men tested in male-only saunas in Melbourne, Australia.

Authors:  Nichole A Lister; Sepehr N Tabrizi; Christopher K Fairley; Anthony Smith; Peter H Janssen; Suzanne Garland
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

Review 8.  The relationship of serovar to clinical manifestations of urogenital Chlamydia trachomatis infection.

Authors:  William M Geisler; Robert J Suchland; William L H Whittington; Walter E Stamm
Journal:  Sex Transm Dis       Date:  2003-02       Impact factor: 2.830

9.  Major outer membrane protein variants of Chlamydia trachomatis are associated with severe upper genital tract infections and histopathology in San Francisco.

Authors:  D Dean; E Oudens; G Bolan; N Padian; J Schachter
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

10.  New lymphogranuloma venereum Chlamydia trachomatis variant, Amsterdam.

Authors:  Joke Spaargaren; Han S A Fennema; Servaas A Morré; Henry J C de Vries; Roel A Coutinho
Journal:  Emerg Infect Dis       Date:  2005-07       Impact factor: 6.883
View more
  8 in total

Review 1.  Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries.

Authors:  R Martin-Iguacel; J M Llibre; H Nielsen; E Heras; L Matas; R Lugo; B Clotet; G Sirera
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-28       Impact factor: 3.267

2.  Development and evaluation of an ompA quantitative real-time PCR assay for Chlamydia trachomatis serovar determination.

Authors:  Matthew P Stevens; Jimmy Twin; Christopher K Fairley; Basil Donovan; Sarah E Tan; Jingxi Yu; Suzanne M Garland; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

Review 3.  Advances in sexually transmitted infections of the gastrointestinal tract.

Authors:  Siew C Ng; Brian Gazzard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08-25       Impact factor: 46.802

4.  Genotyping Chlamydia trachomatis strains among men who have sex with men from a Northern Spain region: a cohort study.

Authors:  P Mejuto; J A Boga; M Junquera; A Torreblanca; P S Leiva
Journal:  BMJ Open       Date:  2013-06-20       Impact factor: 2.692

5.  The association between lymphogranuloma venereum and HIV among men who have sex with men: systematic review and meta-analysis.

Authors:  Minttu M Rönn; Helen Ward
Journal:  BMC Infect Dis       Date:  2011-03-18       Impact factor: 3.090

6.  Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol.

Authors:  Andrew Lau; Fabian Kong; Christopher K Fairley; Basil Donovan; Marcus Chen; Catriona Bradshaw; Mark Boyd; Janaki Amin; Peter Timms; Sepehr Tabrizi; David G Regan; David A Lewis; Anna McNulty; Jane S Hocking
Journal:  BMC Infect Dis       Date:  2017-01-06       Impact factor: 3.090

Review 7.  Chlamydiae from Down Under: The Curious Cases of Chlamydial Infections in Australia.

Authors:  Martina Jelocnik
Journal:  Microorganisms       Date:  2019-11-22

8.  High-resolution genotyping of Lymphogranuloma Venereum (LGV) strains of Chlamydia trachomatis in London using multi-locus VNTR analysis-ompA genotyping (MLVA-ompA).

Authors:  Chloe Manning; Colette O'Neill; Ian N Clarke; Monica Rebec; Penelope R Cliff; Peter Marsh
Journal:  PLoS One       Date:  2021-07-08       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.